19 Papers
Ye E. Li is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
David Marin,Ye E. Li,Rafet Basar,Hind Rafei,May Daher,J. Dou,Vakul Mohanty,Merve Dede,Yago Nieto,Nadima Uprety,S. Acharya,Enli Liu,Jeffrey Wilson,P. Banerjee,Homer A. Macapinlac,Christina Ganesh,Peter F. Thall,R. Bassett,Mariam Ammari,Sheetal S Rao,Kai Cao,Mayra Shanley,Mecit Kaplan,Chitra Hosing,Partow Kebriaei,Loretta J. Nastoupil,Christopher R. Flowers,Sadie Mae Moseley,Paul Lin,Sonny Ang,Uday R. Popat,Muzaffar H. Qazilbash,Richard E. Champlin,Kenneth S. Chen,E. Shpall,Katayoun Rezvani +35 more
TL;DR: Using multiple mouse models, this phase 1/2 trial confirmed the superior antitumor activity of CAR/IL-15 NK cells from optimal CBUs in vivo, uncover new features of CAR-NK cell biology and underscore the importance of donor selection for allogeneic cell therapies.
120
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Ye E. Li,Rafet Basar,Guohui Wang,Enli Liu,Judy S. Moyes,Li Li,Lucila Nassif Kerbauy,Nadima Uprety,Mohsen Fathi,Ali Rezvan,Pinaki P. Banerjee,Luis Muniz-Feliciano,Tamara Laskowski,Emily Ensley,May Daher,Mayra Shanley,Mayela Mendt,Sunil Acharya,Bin Liu,Alexander Biederstädt,Hind Rafei,Xingliang Guo,Luciana Melo-Garcia,Paul Lin,Sonny Ang,David Martin,Kenneth S. Chen,Laura Bover,Richard E. Champlin,Navin Varadarajan,Elizabeth J. Shpall,Katayoun Rezvani +31 more
TL;DR: In this paper , a dual-chimeric antigen receptor (CAR) system was proposed to enhance the antitumor activity of CAR natural killer cells and make them less susceptible to therapeutic resistance in preclinical models.
96
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li Li,Vakul Mohanty,Jinzhuang Dou,Yuefan Huang,Pinaki P. Banerjee,Qi Miao,Jens G. Lohr,Tushara Vijaykumar,Julia Frede,Birgit Knoechel,Luis Muniz-Feliciano,Tamara Laskowski,Shaoheng Liang,Judy S. Moyes,Vandana Nandivada,Rafet Basar,Mecit Kaplan,May Daher,Enli Liu,Ye E. Li,S. Acharya,Paul Lin,Mayra Shanley,Hind Rafei,David Martin,Stephan Mielke,Richard E. Champlin,Elizabeth J. Shpall,Kenneth S. Chen,Katayoun Rezvani +29 more
TL;DR: Interaction with the highly metabolically active tumor resulted in loss of metabolic fitness in NK cells that could be partly overcome by incorporation of IL-15 in the CAR construct.
47
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
TL;DR: The current strategies being explored to improve CAR selectivity toward tumor cells with a focus on natural killer (NK) cells are outlined, and the progress made in translating these strategies to the clinic are outlined.
19
Natural Killer Cells Induce CD8+ T Cell Dysfunction via Galectin-9/TIM-3 in Chronic Hepatitis B Virus Infection
Siyu Liu,Chang Xu,Fan Yang,Lu Zong,Y. Qin,Yufeng Gao,Qian Su,Tuantuan Li,Ye E. Li,Yuan-Hua Xu,Meijuan Zheng +10 more
TL;DR: In vitro depletion of NK cells increased circulating hepatitis B virus (HBV)-specific CD8+ T cell responses in patients with active CHB infection and may be a potential target for the treatment of CHB patients.